Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38147079 | 1.00 | CXCR2 (0.49) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460970 | 1.00 | CXCR2 (0.49) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460679 | 0.91 | CXCR2 (0.51) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL38147084 | 0.91 | CXCR2 (0.51) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460680 | 0.91 | CXCR2 (0.51) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460950 | 0.90 | CXCR2 (0.50) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460975 | 0.90 | CXCR2 (0.50) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460953 | 0.90 | CXCR2 (0.50) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL23460977 | 0.90 | CXCR2 (0.50) | CXCR2MAOBMMEACECPA1 | |
| SCHEMBL38662651 | 0.90 | CXCR2 (0.50) | CXCR2MAOBMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| WO-2021113806-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885MAOB 1413/4885MME 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.